FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

A J G Swaak

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Enzyme-Linked Immunosorbent Assay

Co-author Network

Publications

TOP 3
R A M Quax; A J G Swaak; M G A Baggen
Churg-Strauss Syndrome following PTU Treatment.
J C Drooger; A Dees; A J G Swaak
ANCA-Positive Patients: The Influence of PR3 and MPO Antibodies on Survival Rate and The Association with Clinical and Laboratory Characteristics.
N Bakashvili; A J G Swaak; J W Cohen Tervaert; A Dees
[ANCA(antineutrophil cytoplasmic antibodies)-associated vasculitis in a man with extreme fatigue, fever and progressive renal dysfunction].

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of A J G Swaak (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: R A M Quax; A J G Swaak; M G A Baggen
Churg-Strauss Syndrome following PTU Treatment.
International journal of rheumatology 2009;2009():504105.
2009: J C Drooger; A Dees; A J G Swaak
ANCA-Positive Patients: The Influence of PR3 and MPO Antibodies on Survival Rate and The Association with Clinical and Laboratory Characteristics.
The open rheumatology journal 2009;3():14-7.
2008: N Bakashvili; A J G Swaak; J W Cohen Tervaert; A Dees
[ANCA(antineutrophil cytoplasmic antibodies)-associated vasculitis in a man with extreme fatigue, fever and progressive renal dysfunction].
Nederlands tijdschrift voor geneeskunde 2008;152(17):1009-14.
2007: Johannes C Nossent; Nada Cikes; E Kiss; Antonio Marchesoni; V Nassonova; M Mosca; M Olesinska; G Pokorny; Blaz Rozman; M Schneider; PG Vlachoyiannopoulos; A J G Swaak
Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual.
Lupus 2007;16(5):309-17.
2006: M H W Kappers; A J G Swaak; D M H Zuidgeest; Ad Dees
[Progressive multifocal leukoencephalopathy in a patient following long-term immunosuppressive therapy for systemic lupus erythematosus].
Nederlands tijdschrift voor geneeskunde 2006;150(7):387-92.
2003: Dennis A Hesselink; L A Aarden; A J G Swaak
Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus.
Scandinavian journal of rheumatology 2003;32(3):151-5.
2002: E van Meerten; Arie Berghout; W D H Hendriks; A J G Swaak
[Clinical thinking and decision making in practice. A young woman with fever, arthralgia and exanthema].
Nederlands tijdschrift voor geneeskunde 2002;146(24):1121-5.
2002: Caroline M E Contant; A J G Swaak; A I M Obdeijn; B van der Holt; R Tjong Joe Wai; Albertus N van Geel; Alexander M M Eggermont
A prospective study on silicone breast implants and the silicone-related symptom complex.
Clinical rheumatology 2002;21(3):215-9.
2002: TC Stam; A J G Swaak; Wim H J Kruit; Alexander M M Eggermont
Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b.
European journal of clinical investigation 2002;32 Suppl 1():79-83.
2002: J G den Hollander; A J G Swaak
Essential cryoglobulinaemia (type 1) in three patients characterised by Raynaud's phenomenon, arthralgia-arthritis, and skin lesions.
Annals of the rheumatic diseases 2002;61(1):88-9.
2001: A J G Swaak; HG van den Brink; RJ Smeenk; K Manger; Joachim R Kalden; Silvia Tosi; Z Domljan; Blaz Rozman; Dusan Logar; G Pokorny; L Kovacs; A Kovacs; PG Vlachoyiannopoulos; HM Moutsopoulos; H Chwalinska-Sadowska; E Kiss; Nada Cikes; Branimir Anic; M Schneider; R Fischer; S Bombardieri; M Mosca; W Graninger; Josef S Smolen
Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation.
Lupus 2001;10(1):51-8.
2001: A J G Swaak; H van de Brink ; RJ Smeenk; K Manger; Joachim R Kalden; Silvia Tosi; Antonio Marchesoni; Z Domljan; Blaz Rozman; Dusan Logar; G Pokorny; L Kovacs; A Kovacs; PG Vlachoyiannopoulos; HM Moutsopoulos; H Chwalinska-Sadowska; B Dratwianka; E Kiss; Nada Cikes; Branimir Anic; M Schneider; R Fischer; S Bombardieri; M Mosca; W Graninger; Josef S Smolen
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT).
Rheumatology (Oxford, England) 2001;40(1):89-94.
2000: TC Stam; A J G Swaak; Mark R de Vries; Timo L M ten Hagen; Alexander M M Eggermont
Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage.
Annals of surgical oncology 2000;7(4):268-75.
2000: TC Stam; A J G Swaak; Wim H J Kruit; Gerrit Stoter; Alexander M M Eggermont
Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein response.
European journal of clinical investigation 2000;30(4):336-43.
2000: M N Hylkema; Mieke C J van Bruggen; T ten Hove; J de Jong; A J G Swaak; Jo H M Berden; RJ Smeenk
Histone-containing immune complexes are to a large extent responsible for anti-dsDNA reactivity in the Farr assay of active SLE patients.
Journal of autoimmunity 2000;14(2):159-68.
2000: Caroline M E Contant; A J G Swaak; Theo Wiggers; Rudi Tjong Joe Wai; Albertus N van Geel
First evaluation study of the Dutch Working Party on silicone breast implants (SBI) and the silicone-related symptom complex (SRSC).
Clinical rheumatology 2000;19(6):458-63.
1999: A J G Swaak; HG van den Brink; RJ Smeenk; K Manger; Joachim R Kalden; Silvia Tosi; Antonio Marchesoni; Z Domljan; Blaz Rozman; Dusan Logar; G Pokorny; L Kovacs; A Kovacs; PG Vlachoyiannopoulos; HM Moutsopoulos; H Chwalinska-Sadowska; B Dratwianka; E Kiss; Nada Cikes; A Branimir; M Schneider; R Fischer; S Bombardieri; M Mosca; Josef S Smolen
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation.
Rheumatology (Oxford, England) 1999;38(10):953-8.
1999: Mark R de Vries; IH Borel Rinkes; A J G Swaak; C E Hack; Cornelis J H van de Velde; Theo Wiggers; R A E M Tollenaar; Peter Kuppen; Alexander M M Eggermont
Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.
European journal of clinical investigation 1999;29(6):553-60.
1999: TC Stam; Alexander M M Eggermont; A J G Swaak
Effects of tumour necrosis factor alpha and melphalan on the cytokine production of circulating T cells in patients with cancer.
European journal of clinical investigation 1999;29(3):256-63.
1999: Richard A Feelders; A J G Swaak; J A Romijn; Alexander M M Eggermont; ET Tielens; G Vreugdenhil; E Endert; HG van Eijk; Arie Berghout
Characteristics of recovery from the euthyroid sick syndrome induced by tumor necrosis factor alpha in cancer patients.
Metabolism: clinical and experimental 1999;48(3):324-9.
1999: H R M Peeters; M Jongen-Lavrencic; C H Bakker; G Vreugdenhil; F C Breedveld; A J G Swaak
Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures.
Rheumatology international 1999;18(5-6):201-6.
1998: Richard A Feelders; G Vreugdenhil; Alexander M M Eggermont; P A Kuiper-Kramer; HG van Eijk; A J G Swaak
Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients.
European journal of clinical investigation 1998;28(7):520-7.
1997: A J G Swaak; HG van den Brink; L A Aarden
Cytokine production in whole blood cell cultures of patients with rheumatoid arthritis.
Annals of the rheumatic diseases 1997;56(11):693-5.
1997: M Jongen-Lavrencic; H R M Peeters; A Wognum; G Vreugdenhil; F C Breedveld; A J G Swaak
Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease.
The Journal of rheumatology 1997;24(8):1504-9.
1997: J F Meilof; C H Veldhoven; A J G Swaak; RJ Smeenk
Production of anti-Ro/SS-A and anti-La/SS-B autoantibodies is closely coordinated in systemic lupus erythematosus and independent of anti-dsDNA production.
Journal of autoimmunity 1997;10(1):67-75.
1996: H R M Peeters; M Jongen-Lavrencic; G Vreugdenhil; A J G Swaak
Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial.
Annals of the rheumatic diseases 1996;55(10):739-44.
1996: A J G Swaak; H G van den Brink
Common variable immunodeficiency in a patient with systemic lupus erythematosus.
Lupus 1996;5(3):242-6.
1996: H R M Peeters; M Jongen-Lavrencic; A N Raja; H S Ramdin; G Vreugdenhil; F C Breedveld; A J G Swaak
Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset.
Annals of the rheumatic diseases 1996;55(3):162-8.
1996: M Jongen-Lavrencic; H R M Peeters; Henk Rozemuller; W J Rombouts; Anton Martens; G Vreugdenhil; M Pillay; P H Cox; M Bijser; G Brutel; F C Breedveld; A J G Swaak
IL-6-induced anaemia in rats: possible pathogenetic implications for anemia observed in chronic inflammations.
Clinical and experimental immunology 1996;103(2):328-34.
1996: A J G Swaak; H G van den Brink; L A Aarden
Cytokine production (IL-6 and TNF alpha) in whole blood cell cultures of patients with systemic lupus erythematosus.
Scandinavian journal of rheumatology 1996;25(4):233-8.
1995: M Jongen-Lavrencic; H R M Peeters; G Vreugdenhil; A J G Swaak
Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease.
Clinical rheumatology 1995;14(5):519-25.
1995: M N Hylkema; I V Zwet; C Kramers; Mieke C J van Bruggen; A J G Swaak; Jo H M Berden; RJ Smeenk
No evidence for an independent role of anti-heparan sulphate reactivity apart from anti-DNA in lupus nephritis.
Clinical and experimental immunology 1995;101(1):55-9.
1995: T H Schoonbrood; A Hannema; C A Fijen; H M Markusse; A J G Swaak
C5 deficiency in a patient with primary Sjögren's syndrome.
The Journal of rheumatology 1995;22(7):1389-90.
1995: A J G Swaak; R Q Hintzen; V Huysen; H G van den Brink; J T Smeenk
Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course.
Clinical rheumatology 1995;14(3):293-300.
1994: M N Hylkema; C Kramers; T J Van der Wal; Mieke C J van Bruggen; A J G Swaak; Jo H M Berden; RJ Smeenk
A new ELISA for the detection of anti-heparan sulfate reactivity, using photobiotinylated antigen.
Journal of immunological methods 1994;176(1):33-43.
1994: M N Hylkema; H Huygen; C Kramers; T J vd Wal; J de Jong; Mieke C J van Bruggen; A J G Swaak; Jo H M Berden; RJ Smeenk
Clinical evaluation of a modified ELISA, using photobiotinylated DNA, for the detection of anti-DNA antibodies.
Journal of immunological methods 1994;170(1):93-102.
1994: C Osman; A J G Swaak
Lymphocytotoxic antibodies in SLE: a review of the literature.
Clinical rheumatology 1994;13(1):21-7.
1994: Richard A Feelders; G Vreugdenhil; B Manger; HG van Eijk; A J G Swaak
Serum transferrin receptor levels in anaemia of rheumatoid arthritis and effects of iron chelation treatment.
European journal of haematology 1994;52(1):61-2.
1994: M Jongen-Lavrencic; H R M Peeters; B Backx; I P Touw; G Vreugdenhil; A J G Swaak
R-h-erythropoietin counteracts the inhibition of in vitro erythropoiesis by tumour necrosis factor alpha in patients with rheumatoid arthritis.
Rheumatology international 1994;14(3):109-13.
1994: A P van Dam; E M Wekking; J A Callewaert; A J Schipperijn; H A Oomen; J de Jong; A J G Swaak; RJ Smeenk; T E Feltkamp
Psychiatric symptoms before systemic lupus erythematosus is diagnosed.
Rheumatology international 1994;14(2):57-62.
1993: C Meijer; V Huysen; R T Smeenk; A J G Swaak
Profiles of cytokines (TNF alpha and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease course in patients with systemic lupus erythematosus.
Lupus 1993;2(6):359-65.
1993: M B Andrésdóttir; R Sukhai; A J G Swaak
Polyarteritis nodosa in a young man, a ten-year delay in diagnosis.
Clinical rheumatology 1993;12(3):392-5.
1993: J F Meilof; I M Frohn-Mulder; P A Stewart; A Szatmari; J Hess; C H Veldhoven; RJ Smeenk; A J G Swaak
Maternal autoantibodies and congenital heart block: no evidence for the existence of a unique heart block-associated anti-Ro/SS-A autoantibody profile.
Lupus 1993;2(4):239-46.
1993: Gertjan Wolbink; J Bollen; Joke W Baars; R J ten Berge; A J G Swaak; J Paardekooper; C Erik Hack
Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway.
Journal of immunological methods 1993;163(1):67-76.
1993: M Jongen-Lavrencic; A J G Swaak; G Vreugdenhil
Serial estimation of serum interleukin 6 during treatment with recombinant human erythropoietin in patients with the anemia of rheumatoid arthritis.
The Journal of rheumatology 1993;20(7):1253-5.
1993: Richard A Feelders; G Vreugdenhil; JP van Dijk; A J G Swaak; HG van Eijk
Decreased affinity and number of transferrin receptors on erythroblasts in the anemia of rheumatoid arthritis.
American journal of hematology 1993;43(3):200-4.
1993: S A van der Geest; HM Markusse; A J G Swaak
Beta 2 microglobulin measurements in saliva of patients with primary Sjögren's syndrome: influence of flow.
Annals of the rheumatic diseases 1993;52(6):461-3.
1993: H M Markusse; N J van Haeringen; A J G Swaak; M Hogeweg; P T de Jong
Tear fluid analysis in primary Sjögren's syndrome.
Clinical and experimental rheumatology 1993;11(2):175-8.
1993: A J G Swaak; V Huysen; RJ Smeenk
Antinuclear antibodies in routine analysis: the relevance of putative clinical associations.
Annals of the rheumatic diseases 1993;52(2):110-4.
1993: H M Markusse; C H Veldhoven; A J G Swaak; R T Smeenk
The clinical significance of the detection of anti-Ro/SS-A and anti-La/SS-B autoantibodies using purified recombinant proteins in primary Sjögren's syndrome.
Rheumatology international 1993;13(4):147-50.
1992: G Vreugdenhil; B Manger; C Nieuwenhuizen; Richard A Feelders; HG van Eijk; A J G Swaak
Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis.
Annals of hematology 1992;65(6):265-8.
1992: J J Abbink; A M Kamp; J H Nuijens; A J Erenberg; A J G Swaak; C Erik Hack
Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints.
Annals of the rheumatic diseases 1992;51(10):1123-8.
1992: H M Markusse; M Hogeweg; A J G Swaak; N J van Haeringen; P T de Jong
Ophthalmological examinations of patients with primary Sjögren's syndrome selected from a rheumatological practice.
British journal of rheumatology 1992;31(7):473-6.
1992: C Nieuwenhuizen; G Vreugdenhil; HG van Eijk; A J G Swaak
[Rheumatoid arthritis and anemia; various aspects concerning prevalence, pathogenesis, diagnosis and therapy].
Nederlands tijdschrift voor geneeskunde 1992;136(18):864-8.
1992: A J G Swaak; C Sintnicolaas; C Meijer; R T Smeenk
Observations on the interleukin-6 and acute phase protein profiles in the disease course of patients with lupus erythematosus.
Lupus 1992;1(3):151-5.
1992: H M Markusse; J C Huysen; E J Nieuwenhuys; A J G Swaak
Beta 2 microglobulin in tear fluid from patients with primary Sjögren's syndrome.
Annals of the rheumatic diseases 1992;51(4):503-5.
1992: G Vreugdenhil; C Nieuwenhuizen; A J G Swaak
Interactions between erythropoietin and iron metabolism in anaemia of chronic disorders.
European journal of haematology 1992;48(1):56-7.
1992: A J G Swaak; J C Nossent; RJ Smeenk
Systemic lupus erythematosus.
International journal of clinical & laboratory research 1992;22(4):190-5.
1992: A J G Swaak; E J Nieuwenhuis; RJ Smeenk
Changes in clinical features of patients with systemic lupus erythematosus followed prospectively over 2 decades.
Rheumatology international 1992;12(2):71-5.
1992: Richard A Feelders; G Vreugdenhil; G de Jong; A J G Swaak; HG van Eijk
Transferrin microheterogeneity in rheumatoid arthritis. Relation with disease activity and anemia of chronic disease.
Rheumatology international 1992;12(5):195-9.
1991: J C Nossent; A Hovestadt; D H Schönfeld; A J G Swaak
Single-photon-emission computed tomography of the brain in the evaluation of cerebral lupus.
Arthritis and rheumatism 1991;34(11):1397-403.
1991: J J Abbink; A M Kamp; A J G Swaak; C Erik Hack
Production of monoclonal antibodies against inactivated alpha 1-antitrypsin. Cross-reactivity with complexed alpha 1-antitrypsin and application in an assay to determine inactivated and complexed alpha 1-antitrypsin in biological fluids.
Journal of immunological methods 1991;143(2):197-208.
1991: J J Abbink; A M Kamp; E J Nieuwenhuys; J H Nuijens; A J G Swaak; C Erik Hack
Predominant role of neutrophils in the inactivation of alpha 2-macroglobulin in arthritic joints.
Arthritis and rheumatism 1991;34(9):1139-50.
1991: A J G Swaak; W Bronsveld; E J Nieuwenhuys; J C Nossent; RJ Smeenk
Systemic lupus erythematosus--changing disease patterns in the disease course. Dutch experience with 110 patients studied prospectively.
Rheumatology international 1991;10(6):241-4.
1991: J C Nossent; S C Henzen-Logmans; T M Vroom; V Huysen; Jo H M Berden; A J G Swaak
Relation between serological data at the time of biopsy and renal histology in lupus nephritis.
Rheumatology international 1991;11(2):77-82.
1991: E M Wekking; J C Nossent; A P van Dam; A J G Swaak
Cognitive and emotional disturbances in systemic lupus erythematosus.
Psychotherapy and psychosomatics 1991;55(2-4):126-31.
1991: E M Wekking; A J Vingerhoets; A P van Dam; J C Nossent; A J G Swaak
Daily stressors and systemic lupus erythematosus: a longitudinal analysis--first findings.
Psychotherapy and psychosomatics 1991;55(2-4):108-13.
1991: A J G Swaak; J C Nossent; RJ Smeenk
Prognostic factors in systemic lupus erythematosus.
Rheumatology international 1991;11(3):127-32.
1991: RJ Smeenk; H G van den Brink; K Brinkman; R M Termaat; Jo H M Berden; A J G Swaak
Anti-dsDNA: choice of assay in relation to clinical value.
Rheumatology international 1991;11(3):101-7.
1990: R M Termaat; K Brinkman; J C Nossent; A J G Swaak; RJ Smeenk; Jo H M Berden
Anti-heparan sulphate reactivity in sera from patients with systemic lupus erythematosus with renal or non-renal manifestations.
Clinical and experimental immunology 1990;82(2):268-74.
1990: R Hoekzema; A J G Swaak; M C Brouwer; A van Rooijen; E J Nieuwenhuys; C Erik Hack
Significance of low molecular weight C1q in systemic lupus erythematosus.
Annals of the rheumatic diseases 1990;49(9):698-704.
1990: A J G Swaak; V Huysen; J C Nossent; RJ Smeenk
Antinuclear antibody profiles in relation to specific disease manifestations of systemic lupus erythematosus.
Clinical rheumatology 1990;9(1 Suppl 1):82-94.
1990: J C Nossent; A J G Swaak
Pancytopenia in systemic lupus erythematosus related to azathioprine.
Journal of internal medicine 1990;227(1):69-72.
1989: J C Nossent; W Bronsveld; A J G Swaak
Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively.
Annals of the rheumatic diseases 1989;48(10):810-6.
1989: J C Nossent; V Huysen; RJ Smeenk; A J G Swaak
Low avidity antibodies to dsDNA as a diagnostic tool.
Annals of the rheumatic diseases 1989;48(9):748-52.
1989: J C Nossent; V Huysen; RJ Smeenk; A J G Swaak
Low avidity antibodies to double stranded DNA in systemic lupus erythematosus: a longitudinal study of their clinical significance.
Annals of the rheumatic diseases 1989;48(8):677-82.
1989: A J G Swaak; J C Nossent; W Bronsveld; A van Rooyen; E J Nieuwenhuys; L Theuns; RJ Smeenk
Systemic lupus erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively.
Annals of the rheumatic diseases 1989;48(6):455-60.
1989: A J G Swaak; J C Nossent; W Bronsveld; A Van Rooyen; E J Nieuwenhuys; L Theuns; RJ Smeenk
Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively.
Annals of the rheumatic diseases 1989;48(6):447-54.
1989: Jo H M Berden; R M Termaat; K Brinkman; RJ Smeenk; A J G Swaak; P Faaber; Karel J M Assmann; L P van de Heuvel; J H Veerkamp
Binding of anti-DNA antibodies to glomerular heparan sulfate: a new clue for the pathogenesis of SLE nephritis?
Néphrologie 1989;10(3):127-32.
1989: A J G Swaak; A van Rooyen; L A Aarden
Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus.
Rheumatology international 1989;8(6):263-8.
1988: J C Nossent; A J G Swaak
Pure red-cell aplasia in systemic lupus erythematosus.
Clinical rheumatology 1988;7(4):527-9.
1988: A A Westgeest; H G van den Brink; J de Jong; A J G Swaak; RJ Smeenk
Routine testing for antinuclear antibodies: a comparison of immunofluorescence, counterimmunoelectrophoresis and immunoblotting.
Journal of autoimmunity 1988;1(2):159-70.
1988: A J G Swaak; L L Visch; A Zonneveld
Diagnostic significance of salivary levels of beta 2-microglobulin in Sjögren's syndrome.
Clinical rheumatology 1988;7(1):28-34.
1988: A J G Swaak; H Han; A van Rooyen; M Pillay; C E Hack
Complement (C3) metabolism in rheumatoid arthritis in relation to the disease course.
Rheumatology international 1988;8(2):61-5.
1987: A J G Swaak; A Van Rooyen; O Planten; H Han; O Hattink; E Hack
An analysis of the levels of complement components in the synovial fluid in rheumatic diseases.
Clinical rheumatology 1987;6(3):350-7.
1987: A A Westgeest; H G van den Brink; J de Jong; A J G Swaak; RJ Smeenk
Antinuclear antibodies in patients with systemic lupus erythematosus: a comparison of counterimmunoelectrophoresis and immunoblotting.
Rheumatology international 1987;7(2):77-82.
1986: A J G Swaak; A van Rooyen; C Vogelaar; M Pillay; E Hack
Complement (C3) metabolism in systemic lupus erythematosus in relation to the disease course.
Rheumatology international 1986;6(5):221-6.